Skip to main content

Protagonist Therapeutics, Inc. Shares Fell 54% Yesterday After Abandoning Phase 2 Trial Of Lead Drug

Shares of Protagonist Therapeutics dropped 54% in after-hours trading on Tuesday after announcing it would discontinue phase 2b Propel trial.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.